FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154684369> ?p ?o ?g. }

• W2154684369 endingPage "367" @default.
• W2154684369 startingPage "366" @default.
• W2154684369 abstract "Recent data 1-4 show a high comorbidity between major depressive disorder and metabolic syndrome (MetS) 5, a cluster of risk factors for cardiovascular diseases and type 2 diabetes including high waist circumference, high blood pressure, hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol, and high fasting plasma glucose. In a context of increasing prescription of antidepressant medication 6 and evidence of weight gain induced by antidepressants 7, the impact of antidepressant treatment on MetS has to be clarified. Indeed, there has been no prospective study of reasonable sample size and duration addressing the incidence of MetS in patients with major depressive episode treated with antidepressants. This question was addressed in the METADAP, a 6-month prospective, multicentric, real-world treatment observational cohort study of 624 patients with a diagnosis of major depressive disorder and a current major depressive episode. Data were collected from November 2009 to March 2013 in six university psychiatry departments in France. Consecutive in- or out-patients, aged 18 to 65 years, with a current major depressive episode in a context of major depressive disorder (with a minimum score of 18 at the Hamilton Depression Rating Scale-17, HDRS-17) were assessed for MetS at the start of the index antidepressant treatment (M0), and one (M1), three (M3) and six (M6) months later. All of them provided their written informed consent. Patients with psychotic symptoms, bipolar disorders, psychotic disorders, eating disorders, current substance abuse or dependence, pregnancy, organic brain syndromes or severe unstable medical conditions were not included. Patients receiving antipsychotics or mood stabilizers before inclusion and/or for 4 months or more during the last year were also excluded. Antipsychotics, mood stabilizers and stimulants were not permitted during the study, because of their metabolic effects. Benzodiazepines at the minimum effective dose and for the minimum time period and psychotherapies were allowed. The index antidepressant treatment had to be a monotherapy. The drug and its dose were left to the treating psychiatrist, using “real world” treatment options. MetS was diagnosed according to the International Diabetes Federation definition 8. Participants had to have fasted and abstained from strenuous physical activity for 8 hours before examination. Triglycerides, HDL cholesterol and fasting plasma glucose levels were assessed using routine standardized laboratory methods. Thereafter, an assistant investigator blind to the major depression assessment measured waist circumference and blood pressure. Mixed-effects multivariate models were used, because they are a well-accepted method for analyzing longitudinal clinical data in which missing or mistimed observations are present 9. All regression models included main effects for time since initiation of current antidepressant treatment, age, gender, HDRS-17 score at baseline, lifetime duration of prior major depressive disorder, lifetime duration of prior antidepressant medication, antidepressant-free period before inclusion, and current antidepressant classes. Of 689 pre-included patients, 643 were included, of whom 19 had major deviations to the protocol. Thus, 624 patients were analyzed. Six had missing data for MetS at baseline. Patients’ mean age was 45.6±13.2 years; 68.7% were women, 87.5% were inpatients at baseline. Their mean HDRS-17 score at baseline was 24.7±5.0. Their mean number of previous major depressive episodes was 1.9±2.1. The average lifetime duration of major depressive disorder before inclusion was 11.5±12.2 years. The lifetime duration of antidepressant drug treatment before inclusion was 2.3±4.1 years. Upon inclusion, 22.7% of patients were antidepressant naïve. The administered antidepressant was a selective serotonin reuptake inhibitor (SSRI) in 38.9% of cases, a serotonin norepinephrine reuptake inhibitor (SNRI) in 38.3%, a tricyclic antidepressant (TCA) in 8.8%, and another one in 14.0%. The mean duration of follow-up was 4.9±4.6 months. The drop-out rate was 25.9% before M1, 21.8% between M1 and M3, and 14.3% later. The main reasons for drop-out were antidepressant change (28.4%), prescription of antipsychotics or mood stabilizers (29.4%), and lost to follow-up (20.4%). In patients without MetS at baseline (N=442, 70.8%), the incidence of MetS was 11.7% at M3 and 16.5% at M6. This increase was significant (mixed-effect multivariate logistic regression: OR=2.29, 95% CI: 1.69-3.10, p<0.0001). It was observed within both the SSRI (0% to 16.2%, p<0.001) and the SNRI group (0% to 16.1%, p=0.001). This increase was independent from other factors, such as age, lifetime duration of prior antidepressant medication, and presence of an antidepressant-free period at baseline. The number of altered components of MetS significantly increased with time (M0: 1.2±0.9, M3: 1.3±1.1, M6: 1.5±1.2; mixed-model multivariate Poisson regression: incident risk ratio, IRR=1.06, 95% CI: 1.02-1.09, p<0.0001). It was significantly higher in patients treated with SNRIs than in those treated with SSRIs (IRR=1.45, 95% CI: 1.16-1.80, p=0.001), and it was lower amongst patients who were antidepressant-free at baseline (IRR=0.81, 95% CI: 0.65-0.99, p=0.03). These effects were independent from each other, from age and gender. In patients with MetS at baseline, mixed-effect multivariate linear regressions showed significant increases over time of supine blood pressure (M0: 123.2±16.4 mmHg, M3: 124.8±13.9 mmHg, M6: 126.8±15.0 mmHg, p<0.05) and fasting plasma glucose (M0: 0.98±0.29 g/l, M3: 1.07±0.48 g/l, M6: 1.03±0.31 g/l, p<0.01), which were independent from other factors. The highlight of this study is the early and significant incidence of MetS after initiation of treatment with antidepressants. The majority of cases occurred in the first three months of treatment. A significant worsening of MetS was also observed in patients who already had the syndrome at baseline. Taken together, these results suggest that treating major depressive episodes with antidepressants can induce or worsen MetS. Specific recommendations for the prevention of MetS in patients with major depressive disorder receiving antidepressant medication are needed. Further studies assessing the underlying mechanisms of this phenomenon are warranted. Emmanuelle Corruble1-4, Khalil El Asmar2, Severine Trabado1,3-5, Céline Verstuyft1,3,4,6, Bruno Falissard1-3,7, Romain Colle1-4, Anne-Cécile Petit2, Florence Gressier1-4, Sylvie Brailly-Tabard1,3-5, Florian Ferreri8,9, Jean-Pierre Lépine10, Emmanuel Haffen11, Mircea Polosan12, Céline Bourrier2, Gabriel Perlemuter1,3,13,14, Philippe Chanson1,3-5,15, Bruno Fève9,16,17, Laurent Becquemont1,3,4,6 1University Paris-Sud, Le Kremlin Bicêtre, France; 2Institut National de la Santé et de la Recherche Médicale UMR-1178, Le Kremlin Bicêtre, France; 3Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre, France; 4Hôpital de Bicêtre, Le Kremlin Bicêtre, France; 5Institut National de la Santé et de la Recherche Médicale UMR-S1185, Le Kremlin Bicêtre, France; 6Institut National de la Santé et de la Recherche Médicale U1184, Le Kremlin Bicêtre, France; 7Hôpital Paul Brousse, Villejuif, France; 8Université Pierre et Marie Curie, Paris, France; 9Service de Psychiatrie, Hôpital Saint-Antoine, Paris, France; 10Université Paris Diderot, UMR-S1144, Paris, France; 11Université de Franche-Comté, Besançon, France; 12Grenoble Institut de Neurosciences, Grenoble, France; 13Institut National de la Santé et de la Recherche Médicale UMR-996, Clamart, France; 14Hôpital Antoine-Béclère, Clamart, France; 15Institut National de la Santé et de la Recherche Médicale U1185, Le Kremlin Bicêtre, France; 16Institut Hospitalo-Universitaire ICAN, Paris, France; 17Service d'Endocrinologie, Hôpital Saint-Antoine, Paris, France This study was funded by the Programme Hospitalier de Recherche Clinique National of the French Ministry of Health (AOM06022)." @default.
• W2154684369 created "2016-06-24" @default.
• W2154684369 creator A5003475438 @default.
• W2154684369 creator A5010673180 @default.
• W2154684369 creator A5018886514 @default.
• W2154684369 creator A5024694534 @default.
• W2154684369 creator A5026960163 @default.
• W2154684369 creator A5028728211 @default.
• W2154684369 creator A5033082036 @default.
• W2154684369 creator A5039307785 @default.
• W2154684369 creator A5043690767 @default.
• W2154684369 creator A5053893515 @default.
• W2154684369 creator A5055174925 @default.
• W2154684369 creator A5057701634 @default.
• W2154684369 creator A5060619885 @default.
• W2154684369 creator A5075310433 @default.
• W2154684369 creator A5078636406 @default.
• W2154684369 creator A5086352483 @default.
• W2154684369 creator A5089159383 @default.
• W2154684369 creator A5089604707 @default.
• W2154684369 date "2015-09-25" @default.
• W2154684369 modified "2023-10-18" @default.
• W2154684369 title "Treating major depressive episodes with antidepressants can induce or worsen metabolic syndrome: results of the METADAP cohort" @default.
• W2154684369 cites W1963739832 @default.
• W2154684369 cites W2009064331 @default.
• W2154684369 cites W2021581084 @default.
• W2154684369 cites W2025786817 @default.
• W2154684369 cites W2032228983 @default.
• W2154684369 cites W2075265772 @default.
• W2154684369 cites W2107732097 @default.
• W2154684369 cites W2114964904 @default.
• W2154684369 cites W2163383855 @default.
• W2154684369 cites W4210956151 @default.
• W2154684369 doi "https://doi.org/10.1002/wps.20260" @default.
• W2154684369 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4592664" @default.
• W2154684369 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26407797" @default.
• W2154684369 hasPublicationYear "2015" @default.
• W2154684369 type Work @default.
• W2154684369 sameAs 2154684369 @default.
• W2154684369 citedByCount "42" @default.
• W2154684369 countsByYear W21546843692016 @default.
• W2154684369 countsByYear W21546843692017 @default.
• W2154684369 countsByYear W21546843692018 @default.
• W2154684369 countsByYear W21546843692019 @default.
• W2154684369 countsByYear W21546843692020 @default.
• W2154684369 countsByYear W21546843692021 @default.
• W2154684369 countsByYear W21546843692022 @default.
• W2154684369 countsByYear W21546843692023 @default.
• W2154684369 crossrefType "journal-article" @default.
• W2154684369 hasAuthorship W2154684369A5003475438 @default.
• W2154684369 hasAuthorship W2154684369A5010673180 @default.
• W2154684369 hasAuthorship W2154684369A5018886514 @default.
• W2154684369 hasAuthorship W2154684369A5024694534 @default.
• W2154684369 hasAuthorship W2154684369A5026960163 @default.
• W2154684369 hasAuthorship W2154684369A5028728211 @default.
• W2154684369 hasAuthorship W2154684369A5033082036 @default.
• W2154684369 hasAuthorship W2154684369A5039307785 @default.
• W2154684369 hasAuthorship W2154684369A5043690767 @default.
• W2154684369 hasAuthorship W2154684369A5053893515 @default.
• W2154684369 hasAuthorship W2154684369A5055174925 @default.
• W2154684369 hasAuthorship W2154684369A5057701634 @default.
• W2154684369 hasAuthorship W2154684369A5060619885 @default.
• W2154684369 hasAuthorship W2154684369A5075310433 @default.
• W2154684369 hasAuthorship W2154684369A5078636406 @default.
• W2154684369 hasAuthorship W2154684369A5086352483 @default.
• W2154684369 hasAuthorship W2154684369A5089159383 @default.
• W2154684369 hasAuthorship W2154684369A5089604707 @default.
• W2154684369 hasBestOaLocation W21546843691 @default.
• W2154684369 hasConcept C118552586 @default.
• W2154684369 hasConcept C126322002 @default.
• W2154684369 hasConcept C139719470 @default.
• W2154684369 hasConcept C162324750 @default.
• W2154684369 hasConcept C201903717 @default.
• W2154684369 hasConcept C2776867660 @default.
• W2154684369 hasConcept C2779177272 @default.
• W2154684369 hasConcept C2780051608 @default.
• W2154684369 hasConcept C2780578515 @default.
• W2154684369 hasConcept C2780733359 @default.
• W2154684369 hasConcept C511355011 @default.
• W2154684369 hasConcept C558461103 @default.
• W2154684369 hasConcept C71924100 @default.
• W2154684369 hasConcept C72563966 @default.
• W2154684369 hasConceptScore W2154684369C118552586 @default.
• W2154684369 hasConceptScore W2154684369C126322002 @default.
• W2154684369 hasConceptScore W2154684369C139719470 @default.
• W2154684369 hasConceptScore W2154684369C162324750 @default.
• W2154684369 hasConceptScore W2154684369C201903717 @default.
• W2154684369 hasConceptScore W2154684369C2776867660 @default.
• W2154684369 hasConceptScore W2154684369C2779177272 @default.
• W2154684369 hasConceptScore W2154684369C2780051608 @default.
• W2154684369 hasConceptScore W2154684369C2780578515 @default.
• W2154684369 hasConceptScore W2154684369C2780733359 @default.
• W2154684369 hasConceptScore W2154684369C511355011 @default.
• W2154684369 hasConceptScore W2154684369C558461103 @default.
• W2154684369 hasConceptScore W2154684369C71924100 @default.
• W2154684369 hasConceptScore W2154684369C72563966 @default.
• W2154684369 hasIssue "3" @default.
• W2154684369 hasLocation W21546843691 @default.

• next